Impact of obesity on in-hospital mortality and morbidity among patients admitted for antineoplastic chemotherapy: a nationwide analysis

Clin Transl Oncol. 2024 Apr;26(4):977-984. doi: 10.1007/s12094-023-03335-x. Epub 2023 Nov 10.

Abstract

Background: Obesity is a complex and multifactorial medical condition that can have far reaching consequences on cancer patients, particularly those undergoing treatment such as chemotherapy. Our study focuses to comprehensively explore the various adverse outcomes in obese patients receiving chemotherapy during hospitalization.

Methods: The National Inpatient Sample 2020 was used using the ICD-10 codes to identify patients hospitalized with a primary discharge diagnosis of neoplastic chemotherapy with or without a secondary diagnosis of obesity. Statistical analysis using Stata software was done, and primary and secondary outcomes were obtained after adjusting for confounders using multivariate regression analysis.

Results: Mortality was similar in both obese and non-obese patients. Length of stay and total hospitalization charges were increased in obese patients. Obese patients had higher odds of developing acute respiratory failure and were more likely to require non-invasive and invasive mechanical ventilation.

Conclusion: Our study concluded that obesity could be considered an independent predictor of worse outcomes in patients admitted for neoplastic chemotherapy. Notably, addressing obesity could help to improve the efficacy of treatment for cancer patients while simultaneously reducing any negative consequences associated with being obese.

Keywords: Chemotherapy; NIS; National inpatient sample; Obesity.

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Hospital Mortality
  • Hospitalization
  • Humans
  • Length of Stay
  • Morbidity
  • Neoplasms* / complications
  • Neoplasms* / drug therapy
  • Obesity / complications
  • Obesity / epidemiology

Substances

  • Antineoplastic Agents